Bicara Therapeutics Stock

Bicara Therapeutics, founded in 2020, is a clinical-stage company striving to develop biologics for cancer patient treatments. Bicara uses tumor-targeting antibodies and the tumor-microenvironment aiming to impact the tumor site for a hardwearing effect. Working to advance cancer treatment for patients who have had difficulty with first- and second-line therapies, Bicara partners with chemistry, manufacturing, and controls (CMC) experts and professional protein engineers who have a history of progressing FDA-approved drugs. Bicara Therapeutics is headquartered in Cambridge, Massachusetts.